The Journal Of Medical Research Volume 26

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …. Evidence suggests, Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF …. Analysis reveals, Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). Findings demonstrate, Background Aldosterone dysregulation contributes to hypertension. These findings regarding The Journal Of Medical Research Volume 26 provide comprehensive context for understanding this subject.